ALKERMES | ALKS - Current Assets



ALKERMES reported $1.64B in Current Assets for its fiscal quarter ending in June of 2025.


Current Assets Change Date
AbbVie USD 27.68B 2.09B Mar/2025
Acadia Pharmaceuticals USD 960.55M 89.61M Jun/2025
ALKERMES USD 1.64B 156.24M Jun/2025
Amgen USD 26.73B 195M Jun/2025
Biogen USD 7.97B 341.7M Jun/2025
BioMarin Pharmaceutical USD 3.81B 337.43M Jun/2025
Bristol-Myers Squibb USD 33.22B 2.44B Jun/2025
Eli Lilly USD 49.85B 8.59B Jun/2025
Gilead Sciences USD 14.72B 2.18B Jun/2025
Ionis Pharmaceuticals USD 2.58B 158.22M Jun/2025
J&J USD 71.55B 15.66B Mar/2025
Malin Corporation EUR 62.6M 26.7M Dec/2024
Merck USD 37.07B 1.56B Jun/2025
Neurocrine Biosciences USD 1.75B 111M Jun/2025
Otsuka Holdings JPY 1.39T 72.73B Jun/2025
Pfizer USD 43.7B 2.16B Jun/2025
Regeneron Pharmaceuticals USD 16.86B 712.2M Jun/2025
Vertex Pharmaceuticals USD 10.43B 419.1M Jun/2025